Henoch-Schonlein purpura, also known as IgA vasculitis, is a condition where small blood vessels throughout the body become inflamed and leak, causing a distinctive rash, joint pain, stomach upset, and sometimes kidney involvement. Although it sounds alarming, this disease is most common in children and often resolves on its own within a few weeks, though careful monitoring and supportive treatment play an important role in ensuring the best outcomes.

What happens when blood vessels become inflamed: Goals of treatment in Henoch-Schonlein purpura

When a child or adult is diagnosed with Henoch-Schonlein purpura, the first thing most families want to know is what can be done to help. The good news is that the primary aim of treatment is not necessarily to “cure” the condition, but rather to manage symptoms, ease discomfort, and protect vital organs—especially the kidneys—from long-term damage. Because Henoch-Schonlein purpura is often a self-limiting illness, meaning it tends to go away by itself over time, the role of medical care is mainly to support the body through the acute phase of the disease and watch for any complications that might require more aggressive intervention.^[1][2]

The treatment approach depends heavily on which organs are affected and how severe the symptoms are. For instance, a child with only a rash and mild joint aches might need nothing more than rest and simple pain relief at home, while another child with severe belly pain or signs of kidney trouble might require hospital care and stronger medications. The stage of the illness also matters: early recognition and careful follow-up can prevent serious problems, especially kidney disease, which is one of the most important long-term concerns. Medical guidelines emphasize that treatment must be tailored to each individual patient, considering their age, the severity of their symptoms, and whether there is evidence of organ involvement.^[3][4]

Importantly, while standard therapies focus on symptom relief and monitoring, researchers are also exploring new treatments in clinical trials. These experimental approaches aim to better understand the immune processes that cause Henoch-Schonlein purpura and to develop therapies that might prevent recurrence or reduce the risk of kidney complications. Families should know that treatment is not just about medications; it also involves regular check-ups, urine and blood tests, and sometimes imaging or biopsies to assess how the disease is affecting the body.^[5][6]

Standard treatment approaches: Managing symptoms and protecting the kidneys

Most children and adults with Henoch-Schonlein purpura do not need any specific medication at all. In many cases, the illness resolves on its own within several weeks, and the main role of medical care is to provide comfort and reassurance. The most common form of standard treatment is what doctors call “supportive care,” which means helping the patient feel better while the body heals itself. This includes rest, drinking plenty of fluids to stay hydrated, and using over-the-counter pain relievers to ease joint pain and general discomfort. Paracetamol, known in some countries as acetaminophen, is frequently recommended because it is safe and effective for relieving pain without affecting the kidneys or the digestive system.^[2][4]

For patients who have more troublesome joint pain or swelling, doctors sometimes suggest short courses of anti-inflammatory medicines like ibuprofen or naproxen. However, these drugs belong to a class called non-steroidal anti-inflammatory drugs (NSAIDs), and they must be used with caution. NSAIDs can irritate the stomach lining, which is a concern because many patients with Henoch-Schonlein purpura already have abdominal pain or gastrointestinal bleeding. Additionally, NSAIDs can affect kidney function, so they are typically avoided if there are any signs of kidney involvement, such as blood or protein in the urine. If NSAIDs are used, it is usually for a very short period and only after careful consideration by the doctor.^[8][11]

When a patient has more severe symptoms—such as intense abdominal pain, significant joint swelling, or concerning signs from the kidneys—doctors may turn to a stronger class of medicines called corticosteroids or glucocorticoids. The most commonly used corticosteroid is prednisolone, which is taken by mouth, or methylprednisolone, which can be given through a vein in the hospital. These medicines work by calming down the immune system and reducing inflammation throughout the body. Studies have shown that corticosteroids can shorten the duration of severe abdominal and joint pain, making patients feel better more quickly. They may also help prevent complications such as intussusception, a serious condition where part of the intestine folds into another part, causing a blockage.^[8][13]

The typical dose of oral prednisolone is around 1 to 2 milligrams for every kilogram of the patient’s body weight per day, with a maximum dose of 60 milligrams per day. This is usually given for about one to two weeks, and then the dose is gradually reduced, a process known as “weaning,” to allow the body to adjust as the medicine is stopped. Although corticosteroids can be very helpful in controlling symptoms, they do have side effects, especially when used for long periods. Short courses of a few days to two weeks are generally well tolerated, but longer use can lead to problems like increased appetite, weight gain, mood changes, elevated blood sugar, and a higher risk of infections. For this reason, doctors try to use the lowest effective dose for the shortest time necessary.^[11][14]

Another standard part of care is monitoring blood pressure and testing urine for the presence of blood or protein. About 25 to 50 percent of patients with Henoch-Schonlein purpura develop some degree of kidney involvement, which may not cause any symptoms at first. Blood or protein in the urine, or high blood pressure, are early warning signs that the kidneys are being affected. Most of the time, this kidney involvement is mild and goes away on its own, but a small number of patients can develop more serious kidney disease, which may require stronger treatments. That is why regular follow-up visits and urine tests are recommended for several months after the illness starts, even if the patient feels completely well.^[3][10]

In addition to medications and monitoring, lifestyle measures also play a role. Patients are advised to rest, especially during the acute phase when symptoms are worst. Elevating swollen limbs can help reduce discomfort, and eating a bland diet may ease stomach pain. Adequate hydration is important, particularly if the patient has had vomiting or diarrhea. Parents and caregivers are encouraged to watch for warning signs such as worsening abdominal pain, blood in the stool or urine, severe headache, or confusion, all of which require urgent medical attention.^[4][22]

Treatment in clinical trials: Exploring new therapies to improve outcomes

While most patients with Henoch-Schonlein purpura do well with standard supportive care, researchers continue to study the disease to better understand its causes and to develop more targeted treatments, particularly for patients who have severe or recurring symptoms, or who develop serious kidney disease. Clinical trials are research studies where new drugs or treatment approaches are tested in patients to see if they are safe and effective. These trials are conducted in phases, each designed to answer specific questions about the experimental treatment.^[13][14]

In Phase I clinical trials, the main goal is to determine whether a new drug or therapy is safe for humans. These early-stage studies usually involve a small number of participants and focus on identifying the right dose, how the drug is absorbed and eliminated by the body, and what side effects might occur. For Henoch-Schonlein purpura, Phase I trials might test new immune-modulating drugs that are designed to reduce the abnormal immune response that causes the blood vessel inflammation. Because the disease involves the deposition of a protein called immunoglobulin A (IgA) in the walls of small blood vessels, researchers are interested in therapies that can specifically target this immune pathway.^[3][14]

Phase II clinical trials are the next step and focus on whether the new treatment actually works to improve the disease. These studies enroll a larger number of patients who have Henoch-Schonlein purpura and measure outcomes such as reduction in the rash, improvement in joint pain, resolution of abdominal symptoms, or prevention of kidney damage. Phase II trials also continue to monitor safety and side effects. In recent years, some Phase II studies have explored the use of stronger immunosuppressive drugs, such as azathioprine or cyclophosphamide, in patients with severe kidney involvement. These drugs work by dampening the entire immune system, which can help reduce inflammation and prevent further kidney damage. However, they also carry significant risks, including increased susceptibility to infections and potential long-term effects on bone marrow and fertility, so their use is generally reserved for the most serious cases.^[13][14]

Another area of research involves the use of plasmapheresis, also known as plasma exchange. This is a procedure where the patient’s blood is filtered to remove harmful antibodies and immune complexes, including the IgA deposits that contribute to Henoch-Schonlein purpura. Plasmapheresis has been tested in small clinical trials for patients with severe, rapidly progressing kidney disease. The idea is that by physically removing the harmful proteins from the blood, the inflammation can be reduced and kidney function preserved. Some early results have shown promise, but more research is needed to determine which patients would benefit most from this treatment and how it should be combined with other therapies.^[13][14]

Researchers are also investigating the role of newer biologic therapies, which are drugs made from living cells that target specific parts of the immune system. For example, some biologics block certain immune molecules, called cytokines, that are involved in causing inflammation. Others target immune cells called B cells or T cells, which play a role in producing the IgA antibodies. These treatments are already used for other autoimmune diseases, such as rheumatoid arthritis or lupus, and scientists are exploring whether they might be helpful in Henoch-Schonlein purpura, particularly in patients who do not respond to corticosteroids or who have frequent relapses. Clinical trials are underway in various countries, including the United States, Europe, and Asia, to test these biologic agents in patients with severe or refractory disease.^[14]

Phase III clinical trials compare the new treatment to the current standard of care to see if the experimental therapy is better, worse, or equivalent. These are large studies involving many patients, sometimes across multiple hospitals or countries. For Henoch-Schonlein purpura, a Phase III trial might compare a new biologic drug to corticosteroids, measuring outcomes such as the percentage of patients who achieve complete remission, the time to symptom resolution, or the rate of kidney complications. If the new treatment proves to be more effective or safer, it could eventually be approved by regulatory agencies and become a standard option for patients.^[14]

Finally, Phase IV trials occur after a drug has been approved and is in widespread use. These studies monitor long-term safety and effectiveness in the general population and can identify rare side effects that were not apparent in earlier trials. For Henoch-Schonlein purpura, Phase IV research might track patients over many years to see if new treatments reduce the long-term risk of chronic kidney disease or if they are associated with any unexpected complications.^[14]

Most common treatment methods

• Supportive care
  • Rest and elevation of swollen areas to reduce discomfort and swelling
  • Adequate hydration with water and clear fluids, especially important if there has been vomiting or diarrhea
  • Bland diet to ease abdominal pain and minimize irritation to the digestive system
• Pain relief medications
  • Paracetamol or acetaminophen for mild to moderate pain, safe for kidneys and stomach
  • Short-term use of NSAIDs like ibuprofen or naproxen for joint pain, but only if there is no kidney involvement or gastrointestinal bleeding
• Corticosteroids
  • Oral prednisolone at doses of 1 to 2 milligrams per kilogram per day, typically given for one to two weeks to reduce severe abdominal or joint pain
  • Intravenous methylprednisolone for patients who require hospital care or have very severe symptoms
  • Gradual dose reduction or weaning once symptoms improve to minimize side effects
• Immunosuppressive drugs (for severe kidney involvement)
  • Azathioprine, which suppresses the immune system and may be used in patients with persistent kidney disease
  • Cyclophosphamide, a powerful immune suppressant reserved for the most serious cases with rapidly worsening kidney function
  • Mycophenolate, another immune-suppressing agent sometimes used in combination with corticosteroids
• Plasmapheresis
  • A procedure where the patient’s blood is filtered to remove harmful antibodies and immune complexes
  • May be considered in severe cases with rapidly progressive kidney disease that does not respond to other treatments
• Biologic therapies (experimental, in clinical trials)
  • Drugs that target specific immune molecules or cells, such as cytokine inhibitors or B-cell depleting agents
  • Being studied in clinical trials for patients with severe or refractory disease who do not respond to standard treatments
• Monitoring and follow-up
  • Regular urine tests to check for blood or protein, which are signs of kidney involvement
  • Blood pressure checks to detect hypertension, which can indicate kidney damage
  • Blood tests to assess kidney function and overall health
  • Follow-up appointments for at least six months to a year after the initial illness to catch any late-onset kidney problems